ORYZON Genomics is making changes to its Board of Directors by adding new members.

From GlobeNewswire: 2025-01-27 09:31:22

Oryzon Genomics, S.A. announces changes to its Board of Directors, with four new members to be added. Several independent directors are reaching the 12-year tenure limit. Departing directors include Ramón Adell, Isabel Aguilera, Antonio Fornieles, Josep Ma Echarri, and Dr. Tamara Maes. Dr. Manuel López-Figueroa and Dr. Carlos Buesa will remain, pending shareholder approval. The new directors bring a wealth of experience in medical technology, biotechnology, auditing, and venture capital. Oryzon focuses on epigenetics for therapies in CNS disorders and oncology, with a strong clinical portfolio and advanced pipeline assets. The company is committed to good corporate governance and transparency in all actions.



Read more at GlobeNewswire: ORYZON to Reshape Its Board of Directors at the Upcoming